Related Organizations

ISCT Co-Founded Organizations



Founded in 1996, the Foundation for Accreditation of Cellular Therapy (FACT) establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a non-profit corporation co-founded by the International Society for Cell and Gene Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT) for the purposes of voluntary inspection and accreditation in the field of cellular therapy.

The Joint Accreditation Committee-ISCT & EBMT (JACIE) is a not-for-profit entity established in 1998 for the purposes of assessment and accreditation in the field of haematopoietic stem cell (HSC) transplantation. JACIE's primary aim is to promote high quality patient care and laboratory performance in haematopoietic stem cell collection, processing and transplantation centres through the development of global standards and an internationally recognised system of accreditation.

ISCT Board Representatives:
  • Ngaire Elwood, MSc, PhD
  • Joseph Schwartz, MD, MPH
  • Abba Zubair
  • Nadim Mahmud MD, PhD
  • Patrick Hanley, PhD
  • EJ Shpall, MD

2018 Partner Organization Report

ISCT Board Representatives:
  • Franco Bambi, MD
  • Fermin Sanchez-Guijo, MD, PhD



2018 Partner Organization Report

2017 Annual Report

Other Related Organizations






ISCT Representative, Uniform Donor History Questionnaire, CT Task Force:

  • Phyllis Warkentin, MD

 2018 AABB Interorganizational DHQ - HPC Task Force Partner Organization Report

ISCT Representative, Circular of Information Cell Therapy Task Force (COI CT):

  • J Wade Atkins, MS, MT(ASCP), SB

Circular of Information for the Use of Cellular Therapy Products (2018)

2018 Circular of Information CT Task Force Partner Organization Report

ISCT-AABB Joint Working Group and Human Platelet Lysate Project 



AHCTA (Alliance for Harmonization for Cellular Therapy Accreditation)

ISCT Representative:

  • Karin Hoogendoorn, PharmD

2018 Partner Organization Report

ARM (Alliance for Regenerative Medicine)

ISCT signs Memorandum of Understanding with ARM - April 5, 2016

Standard’s Coordinating Body Representative:

  • Kurt Gunter, MD

2018 Partner Organization Report


American Society for Transplantation and Cellular Therapy (ASTCT)

ISCT is a non-voting board member.

ISCT Representative: 

  • Catherine Bollard, MBChB, MD

ISCT-ASBMT Cellular Therapy Training Course

2018 Partner Organization Report


BAA (Biotherapeutics Association of Australasia)

ISCT Representative:

  • Janice Fogarty, MSc

2018 Partner Organization Report


EATRIS (European Infrastructure for Translational Medicine)

ISCT signs Memorandum of Understanding with EATRIS  — March 7, 2016


SCRM (Strategic Center for Regenerative Medicine)

ISCT Representative:

  • Bryan Choi, PhD


ICCBBA (International Council for Commonality in Blood Banking Automation)

ISCT Representative, Cellular Therapy Coding and Labeling Group (CTLAG) 

  • Leigh Poston, BSc


WBMT (Worldwide Network for Blood & Marrow Transplantation)

ISCT Board Representative:

  • Ed Horwitz, MD, PhD

2018 Partner Organization Report

2017 Annual Report

  USP (United States Pharmacopeial Convention)

ISCT Voting Organizational Member Representative:

  • Joseph Laning, PhD

2015 Convention Resolutions - 2018 Update 

2018 Partner Organization Report

FIRM (Forum for Innovative Regenerative Medicine) 


  •  Kunihiko Suzuki, Vice Chairman
2018 Partner Organization Report

ISO (International Organization for Standardization) 

ISCT Representative, Category A:

  • Sowmya Viswanathan, PhD

2018 Partner Organization Report


The National Academies of Sciences Engineering Medicine - Forum on Regenerative Medicine

ISCT is a member of the National Academies of Sciences, Engineering, and Medicine’s Forum on Regenerative Medicine. The Forum convenes academia, industry, government, patient and provider organizations, regulatory bodies, foundations, societies, associations, and others to discuss challenges facing the application of, and the opportunities for, regenerative medicine to improve health through the development of effective new therapies. The Forum identifies existing and potential barriers to scientific and therapeutic advances; discusses opportunities to assist in facilitating more effective partnerships among key stakeholders; examines the impact that current policies have on the discovery, development, and translation of regenerative medicine therapies; considers the unique challenges of identifying, validating, and bringing regenerative medicine applications to market; and explores the ethical, legal, and social issues posed by regenerative medicine advances.

Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies - A Workshop, Read more

Exploring the State of the Science in the Field of Regenerative Medicine: Challenges of and Opportunities for Cellular Therapies - A Workshop, Read more

For more information about the Forum and our work, please click here.

ISCT Representatives:

  • Daniel Weiss, MD, PhD
  • Karen Nichols, Esq.
  • Bruce Levine, PhD

 2018 Partner Organization Report



CARM (Council for Advanced Regenerative Medicine )

ISCT Representative:

  • Bryan Choi, PhD


© 2020 ISCT. All rights reserved. 
ISCT, INTERNATIONAL SOCIETY FOR CELLULAR THERAPY and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy